← All trials
NCT01122199
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 14, 2010
- Primary completion
- Jan 19, 2015
- Completion date
- Jan 19, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 27
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Big Ten Cancer Research ConsortiumLead sponsor
- Indiana UniversitySponsor investigator
- Indiana UniversityStudy chair
- AmgenCollaborator
- NovartisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.